EyeSpeak: A Real-Time, Non-Invasive Tear Test for Detection of Major Depressive Disorder (MDD)
ISEF · 2024 Translational Medical Science Fourth Award
Overview
Major Depressive Disorder (MDD) affects over 280 million individuals globally, but less than 25% of those affected receive proper care. Early detection is vital for timely intervention and treatment but is hindered by the lack of a definitive clinical test. Current depression detection and diagnoses rely on patient-reported symptoms, lacking quantifiable biomarkers and leading to frequent misdiagnoses. This study aimed to address this gap by investigating tear fluid as a non-invasive point-of-care test for MDD. LC-MS/MS-based proteomics analysis, conducted on samples from 15 MDD patients and 15 healthy controls, yielded a pool of 1,042 tear proteins. Quantitative analysis using MaxQuant and Perseus software packages identified distinct protein expression patterns, revealing 116 upregulated and 89 downregulated proteins in MDD. Applying stringent criteria and comparing with previously reported potential depression biomarkers found in blood and cerebrospinal fluid, three key biomarkers—matrix metalloproteinase-9, interleukin-8, and STAM-binding protein—were selected as tear biomarkers for MDD. ELISA validation demonstrated 100% accuracy in a validation cohort (n=20). For real-time testing, an electrochemical sensor, EyeSpeak was developed using a Sensit Smart biosensor. EyeSpeak demonstrates 99% accuracy, costs 80 cents, and takes 20 minutes for a MDD test. EyeSpeak outperforms the current "gold standard" for MDD diagnosis (PHQ-9 form and psychologist evaluation) by enhancing accuracy by 1.5-fold and saving hundreds of dollars and months of time per patient. This novel approach holds promise as a quantitative gold standard for MDD screening and diagnosis, which could lead to widespread use.
Awards (1)
- Fourth Award of $500 $500
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2019
A Novel Noninvasive and Inexpensive Biomarker for Diagnosing Major Depressive Disorder (MDD): Using Machine Learning Model in silico and Drosophila melanogaster Model in vivo
ISEF · 2025
QuanTear: A Tear Test for Stroke Detection and Monitoring
ISEF · 2020
Development of an Aptamer Based Lateral Flow Test: A Novel Approach to Depression Diagnosis
ISEF · 2026
A Multi-Omics and Machine Learning Approach for Identifying Potential Salivary Biomarkers of and Treating Major Depressive Disorder
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair